Contraindicated (one)bortezomib will enhance the level or influence of mavacamten by impacting hepatic enzyme CYP2C19 metabolism. Contraindicated. Potent or moderate CYP2C19 inhibitors might raise mavacamten systemic publicity, leading to heart failure as a consequence of systolic dysfunction. @fabs Should you preferred this, perhaps would you prefer Open up new window https://sulfo-sanpah-crosslinker11098.blue-blogs.com/32986046/verteporfin-no-further-a-mystery